CAS No.60-32-2,6-Aminocaproic acid Suppliers,MSDS download

Products Categories

Pharmaceutical (171)
Others (46)
Organic Chemicals (44)
Reagent (13)
Materials (3)
Plant Extract (3)
Food Additives (1)

Basic Information

Molecular Structure:
CAS No.:	60-32-2
Name:	6-Aminocaproic acid
Article Data:	115

Formula:	C₆H₁₃NO₂
Molecular Weight:	131.175
Synonyms:	Caproicacid, e-amino- (3CI);6-Amino-n-hexanoic acid;6-Aminocaproic acid;6-Aminohexanoic acid;ACS;Acepramin;Amicar;Amikar;CL10304;CY 116;Caplamin;Capramol;Caprolisin;EACA;Epsamon;Epsicapron;Epsilon S;Hemocaprol;Hemopar;Hepin;NSC 212532;NSC 26154;NSC 400230;e-Amino-n-hexanoic acid;e-Aminocaproic acid;e-Leucine;e-Norleucine;w-Aminocaproic acid;w-Aminohexanoic acid;
EINECS:	200-469-3
Density:	1.042 g/cm³
Melting Point:	207-209 °C (dec.)(lit.)
Boiling Point:	255.6 °C at 760 mmHg
Flash Point:	108.4 °C
Solubility:	soluble in water
Appearance:	white crystalline powder
Hazard Symbols:	Xi
Risk Codes:	36/37/38
Safety:	26-36
PSA:	63.32000
LogP:	1.29040

Raw Materials

100-64-1

105-60-2

57-08-9

Downstream Products

107-95-9

Hot Products

Total:205 Page 1 of 6 1 2 3 4 5 6 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 60-32-2

Consensus Reports

Reported in EPA TSCA Inventory.

Specification

The 6-Aminocaproic acid is an organic compound with the formula C₆H₁₃NO₂. The IUPAC name of this chemical is 6-aminohexanoic acid. With the CAS registry number 60-32-2, it is also named as Acide aminocaproique. The product's categories are Amino Acids; Organic Acids; omega-Aminocarboxylic Acids; omega-Functional Alkanols, Carboxylic Acids, Amines & Halides; Fibrinogen/Thrombin. Besides, it is a white crystalline powder, which should be stored in a closed and dark place.

Physical properties about 6-Aminocaproic acid are: (1)ACD/LogP: -0.11; (2)ACD/LogD (pH 5.5): -2.65; (3)ACD/LogD (pH 7.4): -2.61; (4)ACD/BCF (pH 5.5): 1; (5)ACD/BCF (pH 7.4): 1; (6)ACD/KOC (pH 5.5): 1; (7)ACD/KOC (pH 7.4): 1; (8)#H bond acceptors: 3; (9)#H bond donors: 3; (10)#Freely Rotating Bonds: 6; (11)Polar Surface Area: 29.54 Å²; (12)Index of Refraction: 1.467; (13)Molar Refractivity: 34.94 cm³; (14)Molar Volume: 125.8 cm³; (15)Polarizability: 13.85×10^-24cm³; (16)Surface Tension: 42.6 dyne/cm; (17)Density: 1.042 g/cm³; (18)Flash Point: 108.4 °C; (19)Enthalpy of Vaporization: 54.29 kJ/mol; (20)Boiling Point: 255.6 °C at 760 mmHg; (21)Vapour Pressure: 0.00495 mmHg at 25°C.

Preparation: this chemical is derived from the hydrolysis of caprolactam.

Uses of 6-Aminocaproic acid: it is used to treat excessive postoperative bleeding, especially after procedures in which a great amount of bleeding is indicated, such as cardiac surgery. It can be given orally or intravenously. A meta-analysis found that lysine analogs like aminocaproic acid significantly reduced blood loss in patients undergoing coronary artery bypass grafting. 6-Aminocaproic acid can also be used to treat the overdose and/or toxic effects of the thrombolytic pharmacologic agents tissue plasminogen activator (commonly known as tPA) and streptokinase.

When you are using this chemical, please be cautious about it as the following:
This chemical is irritating to eyes, respiratory system and skin. When you are using it, wear suitable protective clothing. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.

You can still convert the following datas into molecular structure:
(1)SMILES: O=C(O)CCCCCN
(2)InChI: InChI=1/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)
(3)InChIKey: SLXKOJJOQWFEFD-UHFFFAOYAY
(4)Std. InChI: InChI=1S/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)
(5)Std. InChIKey: SLXKOJJOQWFEFD-UHFFFAOYSA-N

The toxicity data is as follows:

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LD50	oral	> 7gm/kg (7000mg/kg)		Drugs in Japan Vol. 6, Pg. 79, 1982.
dog	LDLo	intravenous	2150mg/kg (2150mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Pharmacologist. Vol. 3, Pg. 62, 1961.
guinea pig	LDLo	intravenous	19800mg/kg (19800mg/kg)		Anesthesie, Analgesie, Reanimation. Vol. 22, Pg. 481, 1965.
man	TDLo	multiple routes	14400mg/kg/59 (14400mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS KIDNEY, URETER, AND BLADDER: HEMATURIA	British Journal of Urology. Vol. 60, Pg. 81, 1987.
man	TDLo	oral	1778mg/kg/8D- (1778mg/kg)	KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" KIDNEY, URETER, AND BLADDER: HEMATURIA	American Journal of Kidney Diseases. Vol. 8, Pg. 441, 1986.
monkey	LD50	intravenous	> 2gm/kg (2000mg/kg)		Drugs in Japan Vol. 6, Pg. 79, 1982.
monkey	LD50	oral	> 7gm/kg (7000mg/kg)		Drugs in Japan Vol. 6, Pg. 79, 1982.
mouse	LD50	intravenous	4900mg/kg (4900mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Anesthesie, Analgesie, Reanimation. Vol. 22, Pg. 481, 1965.
mouse	LD50	oral	14300mg/kg (14300mg/kg)		Drugs in Japan Vol. 6, Pg. 79, 1982.
mouse	LD50	subcutaneous	5790mg/kg (5790mg/kg)		Drugs in Japan Vol. -, Pg. 62, 1995.
rabbit	LD50	intravenous	2gm/kg (2000mg/kg)		Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 9, Pg. 759, 1967.
rat	LD	oral	> 10gm/kg (10000mg/kg)		Pharmacologist. Vol. 3, Pg. 62, 1961.
rat	LD50	intraperitoneal	7gm/kg (7000mg/kg)		Pharmacologist. Vol. 3, Pg. 62, 1961.
rat	LD50	intravenous	3300mg/kg (3300mg/kg)		Pharmacologist. Vol. 3, Pg. 62, 1961.
women	TDLo	oral	12600mg/kg/5W (12600mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS BLOOD: "CHANGES IN SERUM COMPOSITION (E.G., TP, BILIRUBIN, CHOLESTEROL)"	Postgraduate Medical Journal. Vol. 55, Pg. 282, 1979.
women	TDLo	oral	33600mg/kg/14 (33600mg/kg)	BEHAVIORAL: MUSCLE WEAKNESS KIDNEY, URETER, AND BLADDER: OTHER CHANGES IN URINE COMPOSITION	Postgraduate Medical Journal. Vol. 55, Pg. 282, 1979.